AIM ImmunoTech Inc.

Listed Company

AIMCIK 0000946644NYSENon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$88.0K

Net Income

$-13.96M

Total Assets

$5.78M

Equity

$-9.78M

Shares Out

14.56M

Op. Cash Flow

$-10.96M

AIM$0.26−97.10% · past yearDBEQ Basic

Daily closing prices

Business

AIM ImmunoTech Inc. is an immuno-pharma company developing nucleic acid and interferon-based therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's primary product, Ampligen (rintatolimod), is a double-stranded RNA molecule in clinical development for pancreatic cancer, other solid tumors, viral infections, and chronic fatigue syndrome; it is approved for commercial sale in Argentina for severe chronic fatigue syndrome. The company also markets Alferon N Injection, an FDA-approved natural alpha-interferon for genital warts, currently not in commercial production. AIM conducts research and development through academic collaborations and early-access programs in Europe, North America, and Latin America.

Summary from 10-K filed 2026-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Clinical treatment programs US	88,000	170,000	202,000	141,000	135,000
Total Revenues	88,000	170,000	202,000	141,000	—
Production costs	128,000	31,000	42,000	—	850,000
Research and development	4	6	11	7	8
General and administrative	8	14	21	13	9
Total Costs and Expenses	12	20	32	20	19
Operating loss	−12	−20	−32	−20	−19
(Loss) gain on investments	17,000	−93,000	200,000	−2	−201,000
Interest and other income	3	5	1	629,000	—
Interest expense	−812,000	−585,000	—	—	−67,000
Issuance cost	−433,000	—	—	—	—
Loss on warrant issuance	−4	—	—	—	—
Change in fair value of warrants	−272,000	−458,000	—	35,000	145,000
Loss from sale of income tax operating losses	—	−2	2	1	2
Net Loss	−14	−17	−29	−19	−19
Basic loss per share	−8.62	−30.92	−0.6	−0.4	−0.4
Diluted loss per share	−8.62	−30.92	−0.6	−0.4	—
Weighted average shares outstanding basic	2	560,169	49	—	—
Weighted average shares outstanding diluted	2	560,169	49	48	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	2	5	27	32
Marketable securities	62,000	2	8	7	16
Other receivable	7,000	—	1	2	—
Prepaid expenses and other current assets	241,000	199,000	302,000	455,000	304,000
Total current assets	3	4	15	36	50
Property and equipment, net	71,000	108,000	127,000	195,000	4
Right of use asset, net	378,000	618,000	697,000	829,000	149,000
Patent and trademark rights, net	2	3	2	2	2
Other assets	377,000	1	2	1	1
Total assets	6	9	19	40	58
Accounts payable	2	6	6	377,000	198,000
Accrued expenses	795,000	606,000	2	806,000	438,000
Current operating lease liability	250,000	239,000	223,000	178,000	37,000
Current note payable, net	4	2	—	—	—
Total current liabilities	6	10	9	1	673,000
Operating lease liability	170,000	395,000	495,000	659,000	112,000
Long-term note payable	927,000	—	—	—	—
Warrant liability	8	—	—	—	—
Total liabilities	16	10	9	2	—
Commitments and contingencies (Notes 7, 8, 10)	—	—	—	—	—
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 3,069,875 and 655,262 as of December 31, 2025 and 2024, respectively	3,000	1,000	49,000	48,000	48,000
Additional paid-in capital	431	426	419	418	417
Accumulated deficit	−441	−427	−410	−381	−361
Total stockholders deficit	−10	−1	10	38	57
Total liabilities and stockholders deficit	6	9	19	40	58

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation of property and equipment	37,000	37,000	39,000	38,000	659,000
Abandonment and expiration of patents and trademark rights	1	48,000	—	—	—
Amortization of patent and trademark rights	173,000	209,000	199,000	218,000	116,000
Non-cash lease expense	294,000	304,000	—	—	—
Amortization of financial obligation	552,000	301,000	—	—	47,000
Equity-based compensation	60,000	686,000	243,000	954,000	2
Non-cash gain on settlement of liability	−3	—	—	—	—
Loss on issuance of warrants	4	—	—	—	—
Loss (gain) on sale of marketable securities	−17,000	93,000	−200,000	2	—
Funds receivable from New Jersey operating loss sales	—	1	492,000	−35,000	34,000
Prepaid expenses and other current assets	−42,000	103,000	153,000	−151,000	2
Lease liability	−268,000	−309,000	−274,000	688,000	−30,000
Other assets	735,000	576,000	−486,000	−83,000	—
Accounts payable	−2	−60,000	6	179,000	−185,000
Other receivable	−7,000	—	—	−35,000	−551,000
Accrued expenses	416,000	−1	1	368,000	−4,000
Net cash used in operating activities	−11	−15	−21	−16	−14
Proceeds from sale of marketable securities	2	6	—	—	—
Purchase of marketable securities	−91,000	−361,000	—	−3	−23
Purchase of property and equipment	—	−18,000	—	−86,000	−41,000
Purchase of patent and trademark rights	−378,000	−538,000	−585,000	−185,000	−592,000
Net cash provided by investing activities	2	5	−832,000	11	−631,000
Proceeds from issuance of liability warrants	7	—	—	—	—
Proceeds from issuance of common stock, net of issuance costs	984,000	892,000	—	—	—
Repayment of debt obligation	−660,000	−251,000	—	—	—
Proceeds from note payable, net of issuance costs	3	3	—	—	—
Proceeds from issuance of equity warrants	—	3	—	—	—
Net cash provided by financing activities	10	6	485,000	80,000	8
Net increase (decrease) in cash and cash equivalents	1	−4	−22	−5	−6
Unrealized gain on marketable investments	73,000	570,000	376,000	−928,000	—
Conversion of Series B preferred	—	689,000	7,000	19,000	17,000
Repayment of debt obligation with shares	700,000	243,000	—	—	—
Operating lease liability arising from obtaining right of use asset	—	31,000	73,000	736,000	—
Cash paid for interest	247,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AIM ImmunoTech Inc.'s CIK number?

AIM ImmunoTech Inc.'s SEC CIK number is 0000946644 (946644). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AIM ImmunoTech Inc.'s SEC filings?

All of AIM ImmunoTech Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AIM ImmunoTech Inc. last report earnings?

AIM ImmunoTech Inc. (AIM) most recently filed an earnings 8-K with the SEC on May 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-024353). This is AIM ImmunoTech Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AIM ImmunoTech Inc.'s most recent earnings 8-K?

AIM ImmunoTech Inc.'s latest earnings 8-K (Item 2.02) was filed May 19, 2026 under accession 0001493152-26-024353. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AIM ImmunoTech Inc.'s latest earnings 8-K →
Look up any company's CIK number →